| 摘要 |
PROBLEM TO BE SOLVED: To provide more effective care of subjects with nonmetastatic breast cancer.SOLUTION: The invention concerns the results obtained in clinical studies of the adjuvant use of HERCEPTIN(R) in human subjects with nonmetastatic, high risk, breast cancer. A method of adjuvant therapy comprises administering to a human subject with nonmetastatic HER2 positive breast cancer, following definitive surgery, an effective amount of an antibody which binds to HER2 Domain IV bound by trastuzumab (HERCEPTIN(R)) and at least one chemotherapeutic agent, so as to extend disease-free survival (DFS) or overall survival (OS) in the subject, wherein the DFS or the OS is evaluated about 2 to 5 years after initiation of treatment. |
